The roles of surgery, stereotactic radiation, and ablation for treatment of pulmonary metastases

J Thorac Cardiovasc Surg. 2022 Feb;163(2):495-502. doi: 10.1016/j.jtcvs.2021.01.143. Epub 2021 Mar 6.

Authors

Mara B Antonoff¹, Constantinos T Sofocleous², Matthew R Callstrom³, Quynh-Nhu Nguyen⁴

Affiliations

¹ Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Tex. Electronic address: mbantonoff@mdanderson.org.
² Department of Interventional Radiology, Memorial Sloan Kettering Cancer Center, New York, NY.
³ Department of Radiology, Mayo Clinic, Rochester, Minn.
⁴ Department of Thoracic Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Tex.

PMID: 33838914
DOI: 10.1016/j.jtcvs.2021.01.143

No abstract available

Keywords: percutaneous ablation; pulmonary metastatic disease; stereotactic body radiotherapy; surgery.

Publication types

Editorial
Review

MeSH terms

Ablation Techniques* / adverse effects
Ablation Techniques* / mortality
Humans
Lung Neoplasms / mortality
Lung Neoplasms / radiotherapy*
Lung Neoplasms / secondary
Lung Neoplasms / surgery*
Metastasectomy* / adverse effects
Metastasectomy* / mortality
Pneumonectomy* / adverse effects
Pneumonectomy* / mortality
Radiosurgery* / adverse effects
Radiosurgery* / mortality
Risk Assessment
Risk Factors
Treatment Outcome